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Aims To investigate whether diabetes confers higher relative rates of cardiovascular events in women compared with




All Danish residents aged 40–89 years without a history major adverse cardiovascular events, including heart failure,
as of 1 January 2012 until 31 December 2016 were categorized by diabetes-status and characterized by individual-
level linkage of Danish nationwide administrative registers. We used Poisson regression to calculate overall and
age-dependent incidence rates, incidence rate ratios, and women-to-men ratios for myocardial infarction, heart fail-
ure, ischaemic stroke, or cardiovascular death (MACE-HF). Among 218 549 (46% women) individuals with dia-
betes, the absolute rate of MACE-HF was higher in men than in women (24.9 vs. 19.9 per 1000 person-years).
Corresponding absolute rates in men and women without diabetes were 10.1 vs. 7.0 per 1000 person-years.
Comparing individuals with and without diabetes, women had higher relative rates of MACE-HF than men [2.8
(confidence interval, CI 2.9–2.9) in women vs. 2.5 (CI 2.4–2.5) in men] with a women-to-men ratio of 1.15 (CI
1.11–1.19, P < 0.001). The relative rates of MACE-HF were highest in the youngest and decreased with advancing
age for both men and women, but the relative rates were higher in women across all ages, with the highest
women-to-men ratio between age 50 and 60 years.
...................................................................................................................................................................................................
Conclusion Although men have higher absolute rates of cardiovascular complications, the relative rates of cardiovascular com-
plications associated with diabetes are higher in women than in men across all ages in the modern era.
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Introduction
Type 2 diabetes (diabetes) and male sex are well-established risk fac-
tors for the development of cardiovascular disease (CVD), but
several studies have shown that the impact of diabetes on CVD may
be greater in women than in men. Older studies have predominantly
observed that women have excess rates of coronary heart disease,1
heart failure,2 stroke,1 CVD-related death,3 and all-cause mortality
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associated with diabetes.4 However, these studies were based on
data collected prior to year 2000 and may not apply in the modern
era due to changes in the definition, incidence, and management of
diabetes over the past two decades.5 In fact, newer studies using data
from the past two decades are inconsistent regarding sex-differences
in the relative rates of coronary heart disease,6–8 heart failure,6,8,9
stroke,6,7,9 death from coronary heart disease,10,11 and all-cause mor-
tality10–12 associated with diabetes. It remains uncertain whether sex-
differences persist in the relative impact of diabetes on CVD and
mortality, and whether these sex-differences depend on age is poorly
investigated. Lastly, whether these sex-differences on the relative im-
pact of diabetes are also present in recurrent events of cardiovascular
complications remain largely unknown.
The aims of this study were, therefore, based on contemporary
data, first to investigate whether diabetes is associated with higher
rates of major adverse cardiovascular events, including heart failure
(MACE-HF), and all-cause mortality in women compared with men,
and if so, whether potential sex-differences in the relative impact of




All residents in Denmark receive a unique and permanent civil registra-
tion number at birth or immigration that enables individual-level linkage
between nationwide registries. Data for this study were obtained from:
(i) the Danish Civil Registration System registry (sex, date of birth, immi-
gration, emigration, and vital status), (ii) the Danish National Patient
Registry [discharge diagnoses coded according to the International
Classification of Diseases (ICD)-8 since 1977, and ICD-10 system since
1994], (iii) the Danish National Prescription Registry [claimed prescrip-
tions since 1995 according to the Anatomical Therapeutic Classification
(ATC)], and (iv) the Danish National Causes of Death Registry (primary
and underlying causes of death from death certificates). All registries have
been validated previously.13,14
Population
Throughout the article, we refer to type 2 diabetes as ‘diabetes’, since we
excluded individuals with type 1 diabetes. The study population com-
prised all individuals in Denmark aged 40–89 years between 1 January
2012 and 31 December 2016. Patients entered the study on 1 January
2012 or when they turned 40, whichever came first. Diabetes-exposure
time was defined as time in study. Incident diabetes was defined by initi-
ation of treatment with an antidiabetic medication (ATC = A10); this def-
inition has a positive predictive value (PPV) of 95% and a sensitivity of
72% in Danish registries.15 We excluded individuals with type 1 diabetes,
defined as monotherapy with insulin (ATC = A10A) before age 30 years.
If the only drug dispensations were metformin (ATC = A10BA02) in
women <40 years of age, the individual was considered to have possible
polycystic ovary syndrome, and these dispensations were not counted.
Thus, claimed prescriptions after age 40 years for women with a diagnosis
of possible polycystic ovary syndrome were considered as diabetes medi-
cations and lead to inclusion at the first date of purchase after the 40th
birthday. For women without diabetes prior to pregnancy [42 weeks
prior to giving birth (ICD-10 codes O80–84)], who claimed a prescription
for insulin between 42 weeks prior to and 30 days after giving birth were
considered as having gestational diabetes, and dispensations of glucose-
lowering medication during and in relation to pregnancy were not consid-
ered. We excluded patients with a diagnosis of coronary artery disease,
heart failure, or ischaemic stroke prior to study entry, as well as individu-
als who immigrated to Denmark after 1 January 2012.
The exposure time of individuals was categorized according to the
presence of diabetes; i.e. each individual contributed to diabetes-free ex-
posure time until the date of diabetes diagnosis and contributed to dia-
betes with exposure time after the date of diagnosis. Patients with a
diagnosis of diabetes and an event of interest on the same day were ana-
lysed as being free of diabetes prior to the event.
Comorbidities (atrial fibrillation, hypertension, dyslipidaemia, chronic
renal failure, and chronic obstructive pulmonary disease) and medications
(antidiabetic, antihypertensive, and anticoagulant drugs and statins) were
identified based on ICD- and ATC-codes (Supplementary material online,
Table S1) for individuals entering the study in 1 January 2012.
Hypertension was defined as treatment with at least two classes of anti-
hypertensive drugs within 180 days prior to 1 January 2012, as previously
validated,16 and dyslipidaemia was defined as claimed prescriptions of
lipid-modifying agents. Medications were defined as dispensed prescrip-
tions within 180 days prior to 1 January 2012.
Outcomes
The primary outcome was MACE-HF, comprising the composite of first-
time myocardial infarction, heart failure, ischaemic stroke, or cardiovascu-
lar death (ICD-10-codes in Supplementary material online, Table S1),
whichever came first. The secondary outcomes were first and second oc-
currence of myocardial infarction, heart failure, ischaemic stroke, and all-
cause mortality. A grace period of 30 days was used for recurrent out-
comes, thus a recurrent outcome could only be classified as a recurrent
outcome 30 days following the first-time event. The diagnoses for the
first-time endpoints have been validated in Danish registers with high
positive predictive value, i.e. 97% (men 97%, women 97%) for myocardial
infarction, 83.6% (men 85.4%, women 81.5%) for heart failure, and 97%
for ischaemic stroke.17–19 The definition of ischaemic stroke included
diagnoses of ischaemic stroke and unspecified stroke, as the majority of
unspecified strokes in prior validation studies were of ischaemic origin.19
Discharge diagnoses for recurrent events have been validated with lower
positive predictive values, i.e. 88% (men 88%, women 87%) for myocar-
dial infarction and 66% for heart failure,17,18 with no validity on recurrent
ischaemic stroke.
Statistics
All individuals were followed from the date of entry until either the first-
time event of interest, death, emigration, age 90 years or 31 December
2016, whichever came first. For recurrent events, all individuals alive
30 days after the first-time event were followed from that day until either
the recurrent event, death, emigration, age 90 years or 31 December
2016, whichever came first.
We present population characteristics on 1 January 2012 as medians
with interquartile ranges for continuous variables, and as counts with per-
centages for categorical variables. We use Poisson regression to calculate
overall and age-dependent incidence rates (IRs), rate ratios (IRRs), and
women-to-men ratios (WMR). We report incidence rates (IR = events/
1000 person-years), incidence rate ratios (IRR = IRdiabetes/IRnon-diabetes),
and women-to-men ratios (WMR = IRRwomen/IRRmen) with 95% confi-
dence intervals (CIs). In age-dependent Poisson regression, age (40–
89 years of age) is divided in 1-year bands and updated consecutively
throughout the study period, allowing to study a non-linear age effect
using thin plate splines.20 We calculate a two-sided P-value for the overall
WMRs. We set the significance level to 5%.






























































































In secondary analyses, we repeat all analyses with first-time myocardial
infarction, first-time heart failure, first-time ischaemic stroke, and all-
cause mortality as outcome, and age-dependent analyses on recurrent
myocardial infarction, heart failure, and ischaemic stroke in the subgroup
of patients with a first-time event, respectively.
We conduct an age-dependent sensitivity analysis for first-time
MACE-HF, excluding individuals with a diagnosis of diabetes and a diagno-
sis of MACE-HF on the same day. We further conduct sensitivity analyses
on first-time MACE-HF and ischaemic stroke, in which age-dependent
analyses are stratified by status of atrial fibrillation, excluding individuals
with a diagnosis of atrial fibrillation and an event of interest on the same
day. All statistical analyses were conducted using R.
Ethics
Retrospective register studies do not need ethical approval in Denmark.
The Danish Data Protection Agency has approved the project (reference
number 2007-58-015/GEH 2014-014, I-Suite no: 02734).
Results
The study included 148 385 (47% women) individuals with prevalent
diabetes on 1 January 2012 (Table 1), 66 078 individuals (46%
women) with incident diabetes between 2012 and 2017, and 4086
individuals (35% women) with diabetes prior to age 40 years, who
were included at age 40 years (Supplementary material online, Figure
S1). Population characteristics in 1 January 2012 showed that individ-
uals with diabetes had higher levels of comorbidities and treated
comorbidities than those without diabetes, but that the comorbid-
ities and treated comorbidities were somewhat similar between men
and women irrespective of diabetes-status (Table 1).
Incidence rates
During above 13 million person-years of follow-up, 121 745 new-
onset MACE-HF events were identified (Table 2), consisting of
30 884 myocardial infarctions, 27 731 heart failures, 40 938 ischaemic
strokes, and 37 096 CVD deaths. There were 7744 MACE-HF events
in women with diabetes over 389 thousand person-years of follow-
up, equal to an IR of 19.9/1000 person-years (Take home figure, Figure
1, Table 2, Supplementary material online, Table S3); there were
45 027 MACE-HF events in women without diabetes over 6.4 million
person-years of follow-up, yielding an IR of 7.0/1000 person-years;
the IRR for women (diabetes:no diabetes) was therefore 2.8 (CI 2.8–
2.9). The corresponding IRR for men was 2.5 (CI 2.4–2.5) based on
IRs of 24.9/1000 person-years in men with diabetes and 10.1/1000
person-years in men without diabetes. The IRR for women was sig-
nificantly higher than the IRR for men: WMR = IRRwomen/IRRmen =
1.15 (CI 1.11–1.19, P < 0.001) (Take home figure, Figure 1). This rela-
tionship was evident for all the secondary outcomes, with WMRs of
1.34 (CI 1.25–1.43, P < 0.001) for myocardial infarction, 1.13 (CI
1.07–1.19, P < 0.001) for heart failure, 1.09 (CI 1.03–1.15, P = 0.004)
for ischaemic stroke, but not for all-cause mortality 1.03 (CI 1.00–
1.06, P = 0.069) (Supplementary material online, Figure S1A–D,
Supplementary material online, Tables S2 and S3).
Age-specific incidence rates
The IRs of MACE-HF and all secondary outcomes increased with
advancing age and were higher in men than in women irrespective of
diabetes-status and age (Figure 2A, Supplementary material online,
Figures S3–S6A). Regardless of diabetes-status and outcome, women
were older than men at time of event with myocardial infarction pre-
senting at the lowest median age (74.4 for women with diabetes, 68.4
for men with diabetes) and heart failure (76.8 for women with dia-
betes, 71.2 for men with diabetes) and all-cause death at the highest
(77.1 for women with diabetes, 73.2 for men with diabetes; Table 2,
Supplementary material online, Tables S2A–S2D).
The sex-specific relative rates (diabetes:no diabetes) for all out-
comes were highest in the youngest individuals and decreased with
advancing age (Figure 2B, Supplementary material online, Figures S3–
S6B). The IRRs for MACE-HF were higher in women than in men at
all ages, with the highest women-to-men ratio between age 50 and
60 years (Figure 2C), although insignificant from age < 45 years.
Somewhat similar findings were evident for all secondary outcomes,
although not in the young for ischaemic stroke (age < 45 years) in
which men had higher relative rates compared with women
(Supplementary material online, Figures S3–S6). Excluding events on
the same day as the diagnosis of diabetes did not change the results
(Supplementary material online, Figures S7–S11).
In individuals without atrial fibrillation, the women-to-men-ratio
for MACE-HF and ischaemic stroke were largely unchanged. In indi-
viduals with atrial fibrillation, we identified 33 513 events of MACE-
HF and 9736 events of ischaemic stroke with a risk-time of 62 000
and 65 000 person-years, respectively (Supplementary material on-
line, Table S4A and B), and we confirmed the findings for MACE-HF,
whereas we observed no sex difference in IRRs of ischaemic stroke
in individuals with atrial fibrillation across all ages (Supplementary ma-
terial online, Figures S12 and S13).
During the 30-day grace period for analyses of recurrent events,
patients were largely excluded due to death, with the highest mortal-
ity among patients with diabetes and the elderly, whereas men and
women had a largely comparable mortality across age-groups regard-
less of diabetes-status (Supplementary material online, Tables S5A–
S5C). Irrespective of diabetes, the IRs of recurrent myocardial infarc-
tion, heart failure, and ischaemic stroke generally increased with
advancing age in men and women (Supplementary material online,
Figures S14–S16A). We observed comparable IRs as well as IRRs in
women and men for all recurrent events across all ages and irrespect-
ive of diabetes status, except for recurrent myocardial infarction in
subgroups of men. In men with diabetes above age 55 years, the IRs
of recurrent myocardial infarction were higher than in men without
diabetes, and in individuals older than age 75 years, we observed
higher IRRs of recurrent myocardial infarction in men than in women
(Supplementary material online, Figures S14–S16B and C).
Discussion
In this nationwide study, we observed that although men have higher
rates of first-time cardiovascular complications, the relative rate of
first-time cardiovascular complications associated with diabetes are
higher in women than in men across all ages in the modern era.
However, in recurrent events these sex-differences in the relative
rate of cardiovascular complications were no longer present.
These results are similar to a study using recent data, which
reported a non-significantly higher relative rate of first-time MACE















(without heart failure), myocardial infarction, and stroke associated
with diabetes in women compared with men,7 but only patients with
newly diagnosed diabetes were included limiting comparisons be-
tween the studies. Interestingly, while their association in relative
rates were attenuated in both sexes from the unadjusted to the fully
adjusted model, their results in WMRs remained unchanged, indicat-
ing that the relation of relative ratios between sexes may not be
affected majorly by these potential confounders. Furthermore, con-
flicting findings from other studies using data from the past two deca-
des are evident, as some studies have observed a significant excess
................................................................. ..................................................................
....................................................................................................................................................................................................................
Table 1 Population characteristics in 1 January 2012
Women Men
No diabetes
(N 5 1 266 291)
Diabetes
(N 5 69 057)
No diabetes
(N 5 1 132 245)
Diabetes
(N 5 79 328)
Age, median (IQR) 57.3 (48.1–67.3) 65.4 (56.1–73.7) 55.2 (47.2–65.0) 63.7 (55.2–70.5)
Comorbidity (%)
Atrial fibrillation 23 380 (1.9) 2998 (4.3) 29.767 (2.6) 4342 (5.5)
Chronic renal failure 4815 (0.4) 1116 (1.6) 5263 (0.5) 1484 (1.9)
COPD 34 610 (2.7) 3.942 (5.7) 24 963 (2.2) 3631 (4.6)
Dyslipidaemia 201 645 (15.9) 51 255 (74.2) 155 692 (13.8) 58 121 (73.3)
Hypertension 189 761 (15.0) 32 948 (47.7) 142 542 (12.6) 36 740 (46.3)
Diabetes duration, years (%)
<5 — 31 873 (46.2) — 37 162 (46.9)
5–10 — 17 469 (25.3) — 20 739 (26.1)
10–15 — 9984 (14.5) — 11 503 (14.5)
>15 — 9731 (14.1) — 9924 (12.5)
Highest attained education (%)
Basic school 385 199 (30.4) 33 419 (48.4) 278 194 (24.6) 27 378 (34.5)
High school 45 917 (3.6) 1647 (2.4) 45 913 (4.1) 2573 (3.2)
Vocational education 438 464 (34.6) 21 109 (30.6) 471 632 (41.7) 32 776 (41.3)
Short/medium length higher education 295 451 (23.3) 9021 (13.1) 194 885 (17.2) 9951 (12.5)
Long higher education, research 70 318 (5.6) 1528 (2.2) 99 966 (8.8) 3980 (5.0)
Unknown 30 942 (2.4) 2333 (3.4) 41 655 (3.7) 2670 (3.4)
Ethnicity (%)a
Danish 1 173 585 (92.7) 60 738 (88.0) 1 041 692 (92.0) 70 363 (88.7)
Immigrants 90 555 (7.2) 8234 (11.9) 88 438 (7.8) 8824 (11.1)
Offspring of first-generation immigrants 2137 (0.2) 85 (0.1) 2101 (0.2) 141 (0.2)
Medicine (%)
Antidiabetics
Metformin — 44 787 (64.9) — 52 720 (66.5)
Insulin — 15 711 (22.8) — 19 592 (24.7)
Sulfonylureas — 12 902 (18.7) — 17 103 (21.6)
GLP1-analogues — 4456 (6.5) — 5243 (6.6)
DPP4-inhibitors — 3128 (4.5) — 3933 (5.0)
Anticoagulants
Aspirin 78 235 (6.2) 20 089 (29.1) 65 458 (5.8) 24 878 (31.4)
ADP-receptor inhibitors 82 326 (6.5) 20 555 (29.8) 68 857 (6.1) 25 353 (32.0)
Vitamin K-antagonists 15 122 (1.2) 2194 (3.2) 20 583 (1.8) 3437 (4.3)
NOAC 2691 (0.2) 234 (0.3) 2479 (0.2) 293 (0.4)
Other
Beta-blockers 96 292 (7.6) 13 183 (19.1) 61 182 (5.4) 12 969 (16.4)
Calcium channel blockers 111 520 (8.8) 18 281 (26.5) 96 816 (8.6) 23 274 (29.3)
RASi 198 103 (15.6) 39 503 (57.2) 169 647 (15.0) 48 304 (60.9)
Statins 151 668 (12.0) 41 897 (60.7) 118 798 (10.5) 47 090 (59.4)
ADP, adenosine diphosphate; COPD, chronic obstructive pulmonary disease; DPP4, dipeptidyl peptidase 4; GLP1, glucagon-like peptide 1; IQR, interquartile range; NOAC,
novel oral anticoagulant; RASi, renin–angiotensin system inhibitors.
aData missing for 56 individuals.
































..rate in women regarding coronary heart disease,6,8 heart failure,8,9
death from coronary heart disease,11 and all-cause death10,11 associ-
ated with diabetes, while others observed no differences between
sexes for heart failure,6 stroke,6 death from myocardial infarction,10
and all-cause mortality.12 Although most of these studies were large,
our study had sufficient power to study sex-differences in all ages,
including sufficient events in the young, and observed that women
had a higher relative rate of MACE-HF and all secondary outcomes
across all ages compared with men, although not at age < 45 years
for ischaemic stroke.
Most studies investigating how sex-differences in the relative im-
pact of diabetes on cardiovascular complications and mortality vary
with age have used wide age-groups, thus not illustrating the full age
effect.6–8,12 A recent study found that the WMRs for cardiovascular
complications were age-dependent, with higher relative rates for cor-
onary heart disease, stroke, and heart failure in women among
younger individuals, with no difference in relative rates from age > 75
years,8 but age at diagnosis among newly diagnosed diabetes were
included limiting the comparison with our study. In contrast to this
and other studies,6,7,12 we observed WMRs to peak in the middle-
aged (age 50–59 years) with lower WMRs at young and old age for
MACE-HF, ischaemic stroke, and all-cause mortality. It is uncertain
why, but all outcomes are rare in young individuals, especially in
women, who generally experience their cardiovascular event and
death later than men,21 thus the increased cardiovascular rate associ-
ated with diabetes may not yet have become apparent in young
women. Furthermore, the level of hypertension is known to increase
at a faster pace with advancing age, especially after menopause, in
women compared with men.22 However, both arguments are in con-
trast with our results for myocardial infarction and heart failure for
which the highest WMRs were observed at youngest age and
decreased with advancing age.
Older studies have observed higher relative rates of recurrent
myocardial infarction23,24 and stroke25 associated with diabetes,
............................................................ ...............................................................
....................................................................................................................................................................................................................
Table 2 Number of events, risk time, and age at MACE-HF according to sex and diabetes-status
Women Men
No diabetes Diabetes No diabetes Diabetes
Number of first-time events and risk time according to age-group (1000 PY)
40–49 2262 (1874) 193 (44) 4567 (1877) 402 (51)
50–59 4469 (1708) 681 (84) 9996 (1643) 1439 (110)
60–69 8463 (1503) 1429 (115) 15 297 (1300) 3185 (149)
70–79 12 830 (940) 2604 (99) 15 691 (700) 3725 (105)
80–89 17 003 (411) 2837 (47) 12 279 (225) 2393 (32)
Total 45 027 (6438) 7744 (389) 57 830 (5745) 11 144 (447)
Median age at time at first-time event (IQR) 75.9 (66.1–83.4) 76.1 (67.9–82.9) 69.3 (59.8–78.4) 71.1 (63.8–78.7)
IQR, interquartile range; MACE-HF, major adverse cardiovascular events including heart failure; PY, person-years.
Take home figure Sex-differences with diabetes. Although men have higher absolute rates of major adverse cardiovascular events including
heart failure, the relative rates of major adverse cardiovascular events including heart failure associated with diabetes are higher in women. IR, inci-
dence rates; IRR, incidence rate ratios; MACE-HF, major adverse cardiovascular events including heart failure; PY, person-years.


























































although none of them showed an age-effect. Contrarily, we
observed broadly comparable rates of all recurrent events between
patients with and without diabetes across all ages, with the exception
of recurrent myocardial infarction in men, in which rates were signifi-
cantly higher from age > 55 years in diabetic men compared with
non-diabetic men. Our study cannot address why we observed a
reduced impact of diabetes on recurrent cardiovascular outcomes
compared with prior studies, but may be secondary to improvements
in risk factor management in patients with diabetes and cardiovascu-
lar complications.5 Two of the prior studies stratified their analyses
by sex and found higher relative rates of recurrent myocardial infarc-
tion in women compared with men.23,24 Conversely, we observed
higher relative rates of myocardial infarction in men from age > 75
years compared with women, and no difference in relative rates of
recurrent discharge of heart failure and ischaemic stroke across all
ages between men and women.
Diabetes may confer higher relative rates of first-time cardiovascu-
lar complications in women because of interaction with sex hor-
mones, since diabetes appears to attenuate the protective effect of
oestrogen regarding atherosclerosis,26 as supported by the declining
WMR of first-time events with advancing age as observed in our
results. Other explanations could be differences in the cardiovascular
risk factor burden, sex-differences in the healthcare provided for the
prevention, management and treatment of diabetes and its complica-
tions (e.g. worse glycaemic control in women),27 or women being
less adherent to guideline-recommended treatment.28 Given the
lower absolute rate of CVD in women than in men, these findings
may merely be explained by a comparable rate difference that leads
to higher relative rates in women. It is unknown why these sex-
differences appeared to diminish for recurrent events, but potentially
secondary prophylaxis in patients with established cardiovascular
complications attenuates the observed sex-differences, men and
women are more equal regarding recurrent CVD events associated
with diabetes in individuals with established CVD, or our population
with first-time events was too small to detect statistically significant
sex-differences.
Strengths and limitations
The major strengths of this nationwide study include minimal risk of
selection bias, minimal loss to follow-up ensured by the comprehen-
sive Danish registries and the large sample size with more than 13
million person-years. This enabled us to study sex-differences in asso-
ciations between diabetes on cardiovascular events and mortality
with sufficient power in all ages following the introduction of the new
diabetes definition in Denmark at 1 January 2012 over a relatively
short study period, but important limitations need to be addressed.
The primary limitation to this study is that our results rely on dis-
charge diagnoses of myocardial infarction, heart failure, ischaemic
stroke, and cardiovascular death reported in the medical charts at
the hospitals and not on clinical data,29 but potential minor misclassifi-
cations are non-systematic and do not influence the overall validity of
the data.13 Although the diagnoses of diabetes, myocardial infarction,
and ischaemic stroke have high positive predictive values, and myo-
cardial infarction a high sensitivity,29 PPVs by sex for diabetes and is-
chaemic stroke are unknown, and recurrent outcomes are validated
with relatively lower PPVs. An older study revealed a high PPV and
specificity, but a low sensitivity for the heart failure diagnosis of
29%,30 which should be acknowledged in the interpretation of the
results. Furthermore, we cannot rule out that the true rates of dia-
betes, particularly all diet-treated cases, and cardiovascular events
may have been underestimated, which may have biased our results.
However, despite these limitations, our results generally concur with
previous studies exploring sex-differences in the relative impact of
diabetes on CVD and mortality.
Secondly, we did not have access to information on metabolic
control (glucose-levels, lipids, and blood pressure), imaging
Women
     No diabetes
     Diabetes
Men
     No diabetes
     Diabetes
0 10 20 30
Incidence rate
(events/1,000 PY)
1 2 3 4
Incidence rate ratio
(IR−diabetes/IR−no diabetes)
0.9 1 1.1 1.2
Women−to−men ratio
(IRR−women/IRR−men)
Figure 1 Overall incidence rates, incidence rate ratios, and women-to-men ratios of first-time major adverse cardiovascular events including heart
failure, stratified by diabetes-status (incidence rates only) and sex (incidence rates and incidence rate ratios only). Higher incidence rate ratio in men if
women-to-men ratios <1, and higher incidence rate ratio in women if women-to-men ratios >1. IR, incidence rates; IRR, incidence rate ratios;
MACE-HF, major adverse cardiovascular events including heart failure; PY, person-years; WMR, women-to-men ratios.


















..(echocardiography including measures of diastolic function), or life-
style factors (smoking, alcohol consumption, body mass index, phys-
ical activity level, or diet).
Thirdly, since the majority of diagnoses of gestational diabetes and
polycystic ovary syndrome are diagnosed in private practice, we used
prescribed antidiabetics to define both diagnoses, which have not
been validated. Our definitions capture women with gestational dia-
betes treated with insulin during pregnancy along with women with
polycystic ovary syndrome treated with metformin. Although this
also excluded women in monotherapy of metformin age < 40 years
due to a diagnosis of diabetes from the diabetes exposure-time, these
women would re-enter from age 40 years if still claiming prescrip-
tions for antidiabetic medication. Women with polycystic ovary syn-
drome treated with metformin age > 40 years were not accounted
for, thus may have contributed with risk time without many events,









































































Figure 2 (A–C) Incidence rates (A), incidence rate ratios (B), and women-to-men ratios (C) of first-time major adverse cardiovascular events includ-
ing heart failure according to age, stratified by diabetes-status (incidence rates only) and sex (incidence rates and incidence rate ratios only). Higher in-
cidence rate ratio in men if women-to-men ratios <1, and higher incidence rate ratio in women if women-to-men ratios >1. IR, incidence rates; IRR,
incidence rate ratios; MACE-HF, major adverse cardiovascular events including heart failure; PY, person-years; WMR, women-to-men ratios.





















































































..as diabetes. However, this is considered to be a minor group of
women, thus it unlikely affected our results significantly.
Lastly, the majority of the Danish population is Caucasian, and we
did not include individuals immigrating to Denmark during our study
period due to unknown medical history, thus our results may not be
generalizable to non-Caucasian people.
Conclusions
In this nationwide study, we observed that although men have higher
absolute rates of first-time cardiovascular complications, the relative
rate of first-time cardiovascular complications are higher in women
than in men across all ages in the modern era. Secondly, these sex-
differences are not present in recurrent cardiovascular outcomes.
Further studies are warranted to more clearly elucidate the mecha-
nisms responsible for the substantial sex-differences in diabetes-
related first-time cardiovascular complications.
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